ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMN ProMIS Neurosciences Inc

Market Closed 04-11 16:00:00 EDT

0.5596

+0.0071

+1.29%

High0.6391	Low0.5111	Vol41.46K
Open0.5530	D1 Closing0.5525	Amplitude23.17%
Mkt Cap18.29M	Tradable Cap9.77M	Total Shares32.69M
T/O23.53K	T/O Rate0.24%	Tradable Shares17.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"PMN","market":"US","secType":"STK","nameCN":"ProMIS Neurosciences Inc","latestPrice":0.5596,"timestamp":1744401600000,"preClose":0.5525,"halted":0,"volume":41463,"delay":0,"floatShares":17461973,"shares":32689190,"eps":0.107209,"marketStatus":"Market Closed","change":0.0071,"latestTime":"04-11 16:00:00 EDT","open":0.553,"high":0.63913,"low":0.5111,"amount":23532.460488,"amplitude":0.231729,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.107209,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.5525,"volumeRatio":0.9151000474094789},"requestUrl":"/m/hq/s/PMN","defaultTab":"news","newsList":[{"id":"2524214324","title":"ProMIS Neurosciences Price Target Maintained With a $6.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2524214324","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524214324?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:06","pubTimestamp":1743519960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 11:06 ET (15:06 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN"],"gpt_icon":0},{"id":"2524908766","title":"ProMIS Neurosciences Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524908766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524908766?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 05:30","pubTimestamp":1743456659,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc reports results for the quarter ended December 31 - Earnings SummaryProMIS Neurosciences Inc PMN.OQ reported a quarterly adjusted loss of 1 cent per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE1R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN"],"gpt_icon":0},{"id":"2523091018","title":"ProMIS Neurosciences FY 2024 GAAP EPS $0.11 May Not Be Comparable To $(0.06) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523091018","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523091018?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:23","pubTimestamp":1743420206,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (NASDAQ:PMN) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.06) by 283.33 percent. This is a 110.28 percent increase over losses of $(1.07) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44558656/promis-neurosciences-fy-2024-gaap-eps-0-11-may-not-be-comparable-to-0-06-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN"],"gpt_icon":0},{"id":"2523920917","title":"ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2523920917","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523920917?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:05","pubTimestamp":1743419122,"startTime":"0","endTime":"0","summary":"“2024 was a transformational year for ProMIS Neurosciences (PMN) as we reached a major milestone with the initiation of our 100-patient Phase 1b cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-reports-fy24-eps-11c-vs-1-07-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-reports-fy24-eps-11c-vs-1-07-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2523917896","title":"ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917896","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917896?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease. PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026. CAMBRIDGE, Massachusetts, March 31, 2025  -- ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease , amyotrophic lateral sclerosis  and multiple system atrophy , today announced financial results for the fiscal year ended December 31, 2024 and provided a corporate update.Based on the encouraging results from the Phase 1a study of PMN310, ProMIS initiated a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/promis-neurosciences-announces-full-2024-110000013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","BK4218","LU1169590202.USD","BK4023","LU2463526074.USD","IE00B3T34201.USD","LU1169589451.USD","BK4588","PK","LU0728928796.USD","LU1487256676.USD","AAN","MSA","LU2125909759.SGD","BK4136","LU0757428866.USD","LU1923622291.USD","PIPE","BK4139","BK4178","BK4585","LU2211815571.USD","LU1815336091.USD","LU1481600234.SGD","IP","LU2125909916.SGD","BK4181","LU1481599808.USD","PMN","BK4143","PD"],"gpt_icon":0},{"id":"2523636880","title":"ProMIS Neurosciences Inc  expected to post a loss of 14 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523636880","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523636880?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 05:10","pubTimestamp":1743196215,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc  expected to post a loss of14cents a share - Earnings Preview ProMIS Neurosciences Inc PMN.OQ PMN.O is expected to show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB1VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN"],"gpt_icon":0},{"id":"2519891662","title":"Danantara Won't Pledge Government Shares, Says Deputy Minister of Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2519891662","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519891662?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 08:06","pubTimestamp":1741910760,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta - Deputy Minister of Finance Thomas Djiwandono addressed the role of the Sovereign Wealth Fund, Danantara. He clarified that the investment institution is designed to bolster the function of state-owned enterprises .Thomas, who is the nephew of President Prabowo Subianto, emphasized that Danantara has the authority to manage dividends. However, he ensured that it will not engage in the pawning of government shares in SOEs.\"It needs to be emphasized that Danantara will not pledge government shares. Government shares are underlying assets that generate dividends, which Danantara will use for investment purposes,\" he said during a State Budget press conference at the Finance Ministry office in Jakarta on Thursday, March 13, 2025.","market":"other","thumbnail":"https://statik.tempo.co/data/2024/07/19/id_1320120/1320120_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2024/07/19/id_1320120/1320120_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1986298/danantara-wont-pledge-government-shares-says-deputy-minister-of-finance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2514853378","title":"Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514853378","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514853378?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:25","pubTimestamp":1740576300,"startTime":"0","endTime":"0","summary":"-- On track to announce the primary endpoint result from the atacicept. pivotal Phase 3 ORIGIN trial in IgA Nephropathy  in 2Q 2025; BLA. submission to the U.S. FDA for accelerated approval planned in 2H 2025. -- Expanded atacicept clinical development program in multiple autoimmune. planned FDA submission, and potential 2026 commercial launch of atacicept. \"Vera is poised to change the standard of care in autoimmune diseases with atacicept, our investigational therapy, beginning with IgA nephropathy. We are on track to announce the primary endpoint result of the ORIGIN Phase 3 study in the second quarter of this year. We look forward to submitting a Biologics License Application  for this potential best-in-class therapy in the second half of this year. We are grateful to the study investigators and participants for their ongoing and enthusiastic participation in this program,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"In addition, over the past year we have m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BJJMRY28.SGD","BK4585","MCD","LU0868494708.USD","FSGS","BK4550","LU1244550494.USD","LU1244550221.USD","LU0942090050.USD","BK4139","LU0417517546.SGD","BK4504","BK4213","IE00BFSS7M15.SGD","LU0256863811.USD","IE00BJTD4N35.SGD","LU1244550577.SGD","BK4534","BKV","BK4566","LU1585245621.USD","IE00BFSS8Q28.SGD","IE00BJTD4V19.USD","IE00B7KXQ091.USD","IE00BJJMRX11.SGD","BK4581","VERA","LU1718418525.SGD","LU1430594728.SGD","PMN","BK4209","IE0004445015.USD","TACI","LU0868494617.USD","LENZ","LU2133065610.SGD"],"gpt_icon":0},{"id":"2514893093","title":"ProMIS Neurosciences Inc - Six-Month Interim Results Expected in 1H 2026, Topline Results in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2514893093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514893093?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA3TWZKR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2514098588","title":"ProMIS Neurosciences Doses First Patients in Phase 1B Precise-Ad Trial of Pmn310 for Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2514098588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514098588?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA3TWZKR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2514093869","title":"ProMIS Neurosciences Inc - Precise-Ad Study to Enroll Approximately 100 Subjects Across 22 Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2514093869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514093869?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA3TWZKR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2514098211","title":"ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2514098211","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514098211?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease. Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026. “As physicians dedicated to advancing Alzheimer’s research, we are excited to be part of the PRECISE-AD trial evaluating PMN310,” said Yaneicy Gonzalez-Rojas, M.D. and Ahmad Aswad, M.D., Investigators of the PRECISE-AD clinical trial. “Alzheimer’s disease remains one of the greatest unmet medical needs, and patients urgently need new treatment options that are both effective and well-tolerated. Current AD treatments offer only modest efficacy and are often accompanied by significant side effects, such as ARIA. PMN310’s n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/promis-neurosciences-doses-first-patients-120000823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0053671581.USD","BK4218","LU2125909916.SGD","MSA","PK","LU2125909759.SGD","LU1815336091.USD","PMN","LU0728928796.USD","LU2211815571.USD","BK4143","LU1923622291.USD","LU0757428866.USD","BK4181"],"gpt_icon":0},{"id":"2512458823","title":"ProMIS Neurosciences seperates from COO Malenfant, terminates COO position","url":"https://stock-news.laohu8.com/highlight/detail?id=2512458823","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512458823?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 06:10","pubTimestamp":1740003035,"startTime":"0","endTime":"0","summary":"On February 14 ProMIS Neurosciences (PMN) separated with Gavin T. Malenfant as Chief Operating Officer of the Company, effective as of February 14…...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-seperates-from-coo-malenfant-terminates-coo-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-seperates-from-coo-malenfant-terminates-coo-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1992135472.HKD","GB00BDT5M118.USD","BK4198","LU2272731600.USD","BK4585","BK4588","LU2211815571.USD","PMN","COO","LU1992135399.USD","LU2272731782.SGD","BK4139"],"gpt_icon":0},{"id":"2512526591","title":"World First: TMC and PAMCO Achieve a New Nodule Processing Milestone, Unlocking Critical Energy & Steelmaking Materials at Existing Facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2512526591","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512526591?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 21:05","pubTimestamp":1739883900,"startTime":"0","endTime":"0","summary":"During the processing campaign, PAMCO operators fed calcine material into an electric-arc furnace, producing high-grade nickel-copper-cobalt alloy  and manganese silicate products.TMC and PAMCO have successfully demonstrated the production flowsheet for its initial commercial production using a 2,000-tonne sample of nodules collected during TMC subsidiary Nauru Ocean Resources Inc.’s 2022 test mining, at PAMCO’s commercial operating facility in Hachinohe, Japan. Following the recovery of 3,000 tonnes of nodules during 2022 test mining by TMC’s subsidiary Nauru Ocean Resources Inc  from its exploration contract area D in the Clarion Clipperton Zone , 2,000 tonnes were delivered to PAMCO’s RKEF plant to go through a feasibility program consisting of calcining and smelting campaigns. Following the commercial-scale production of calcine in September 2024, over a 14-day continuous smelting campaign in January and February 2025, PAMCO operators fed approximately 450 tonnes of calcine materia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/world-first-tmc-pamco-achieve-130500735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARKG","BK4168","BK4563","BK4585","CCZ","BK4544","BK4588","PMN","TMCWW","TMC","BK4139"],"gpt_icon":1},{"id":"2503584309","title":"ProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26","url":"https://stock-news.laohu8.com/highlight/detail?id=2503584309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503584309?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 23:55","pubTimestamp":1736783724,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (PMN) announced that its CEO Neil Warma, issued a letter to the company’s shareholders, the company said, “In my first year as...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-anticipates-precise-ad-interim-patient-data-in-1h26?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-anticipates-precise-ad-interim-patient-data-in-1h26?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2502854297","title":"ProMIS Neurosciences Inc - Study to Enroll 100 Subjects Across 22 U.S. Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2502854297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502854297?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA9HYZQK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2502854248","title":"ProMIS Neurosciences Inc - Phase 1a Study Shows Favorable Safety Profile for Pmn310","url":"https://stock-news.laohu8.com/highlight/detail?id=2502854248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502854248?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA9HYZQK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2502854244","title":"ProMIS Neurosciences Inc - Patients to Be Dosed Monthly for 12 Months in Phase 1B Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2502854244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502854244?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA9HYZQK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2502544528","title":"ProMIS Neurosciences Initiates Phase 1B Clinical Trial (Precise-Ad) in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2502544528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502544528?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA9HYZQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2502040333","title":"Verizon named a Leader in first-ever 2025 Gartner® Magic Quadrant™ for Private Mobile Network Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2502040333","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502040333?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 01:36","pubTimestamp":1736444160,"startTime":"0","endTime":"0","summary":"Verizon is the only U.S.-based service provider to be named a Leader, placed in the report for both “Completeness of Vision” and “Ability to Execute.”NEW YORK, Jan.  09, 2025  (GLOBE NEWSWIRE) -- Veri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007274/0/en/Verizon-named-a-Leader-in-first-ever-2025-Gartner-Magic-Quadrant-for-Private-Mobile-Network-Services.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4534","LU1162221912.USD","LU1066051498.USD","IE00BSNM7G36.USD","BK4581","BK4515","LU0098860793.USD","BK4139","LU1059921491.USD","LU0321505868.SGD","PMN","LU1366192091.USD","LU0868494708.USD","LU1066051811.HKD","VZ","BK4550","LU1585245621.USD","LU1430594728.SGD","LU0306806265.USD","LU1066051225.USD","BK4585","LU0225284248.USD","LU0320765646.SGD","LU1621768115.EUR","LU2384288077.EUR","BK4559","BK4588","LU0306807586.USD","BK4533","LU1571399168.USD","LU1699723380.USD","LU0321505439.SGD","LU1621767737.EUR","LU1914381329.SGD","LU1621768206.USD","LU0985481810.HKD","LU0225771236.USD","BK4115","LU0942090050.USD","LU1621767810.EUR","LU0868494617.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.promisneurosciences.com","stockEarnings":[{"period":"1week","weight":-0.0884},{"period":"1month","weight":-0.2674},{"period":"3month","weight":-0.4567},{"period":"6month","weight":-0.4514},{"period":"1year","weight":-0.7619},{"period":"ytd","weight":-0.4096}],"compareEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0446},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0787},{"period":"1year","weight":0.0308},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","exchange":"NASDAQ","name":"ProMIS Neurosciences Inc","nameEN":"ProMIS Neurosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.4","shortVersion":"4.32.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProMIS Neurosciences Inc,PMN,ProMIS Neurosciences Inc股票,ProMIS Neurosciences Inc股票老虎,ProMIS Neurosciences Inc股票老虎国际,ProMIS Neurosciences Inc行情,ProMIS Neurosciences Inc股票行情,ProMIS Neurosciences Inc股价,ProMIS Neurosciences Inc股市,ProMIS Neurosciences Inc股票价格,ProMIS Neurosciences Inc股票交易,ProMIS Neurosciences Inc股票购买,ProMIS Neurosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction